Pharmaceutical Technology

MAY 18, 2023

Other investors include Investissement Québec, Omega Funds, Cowen Healthcare Investments, CTI Life Sciences Fund III, Northleaf Capital Partners, BVF Partners and Vivo Capital. The combined company will be named enGene Holdings and its common shares are expected to be listed on the Nasdaq.

Gene Therapy 130

Gene Therapy Gene In-Vivo Life Science 130

XTalks

DECEMBER 20, 2023

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

Drug Discovery World

DECEMBER 21, 2022

It covers an article by the same name written for Volume 23, Issue 1 – Winter 2021/22 of DDW.

In-Vivo 52

In-Vivo Drugs Life Science Medicine 52

XTalks

APRIL 14, 2022

Conventional in vitro and in vivo studies are used in the drug development pipeline. However, could there be another way for developing biomedical products using in silico technology? This involves the use of an individualized computer simulation for medical device or drug development. Want to learn more?

Trials 98

Trials In-Vivo In-Vitro Clinical Trials 98

Drug Discovery World

APRIL 10, 2023

Diana Spencer explores the evolution of the Hyderabad life sciences hub. Thanks to a new focus on R&D, increasing digitalisation and government investment, India is establishing itself as a significant player in drug discovery, and the Hyderabad life sciences hub has played a significant role in this.

Genome 52

Genome Genomics Drugs Life Science 52

pharmaphorum

MAY 27, 2021

Life sciences tools company Esco Lifesciences Group has scored $200m in a series A and crossover round co-led by Novo Holdings and Vivo Capital. The deal was described by the companies as the largest private financing round for an Asia-based life sciences tools company.

Life Science 59

Life Science In-Vivo Manufacturing Gene Therapy 59

pharmaphorum

JANUARY 13, 2021

The financing round was led by HBM Healthcare Investments with the participation of existing investors Novo Seeds, Lundbeckfonden Emerge and Sunstone Life Science Ventures. IO102 and IO103 are cancer first-in-class vaccines based on IO Biotech’s proprietary T-win technology platform.

Vaccination 95

Vaccination Vaccine Development In-Vivo 95

The Pharma Data

JANUARY 17, 2021

Based in Seattle, Washington, Sana focuses on in vivo and ex vivo cell engineering platforms to develop therapies for cancer, diabetes, cardiovascular disease, CNS disorders, and genetic diseases. But that number doesn’t quite reflect the company’s likely market valuation , which is expected to be between $9 billion and $12 billion.

In-Vivo 52

In-Vivo Marketing Engineer Genetics 52

The Pharma Data

JANUARY 6, 2021

SK Chemicals has shared their expertise in these diseases and validated the predicted targets and compounds through in vitro and in vivo studies. SK Chemicals is a leading company in the fields of chemistry and life science. SK Chemicals is a leading company in the fields of chemistry and life science.

FDA Approval 52

FDA Approval Life Science Drugs In-Vivo 52

pharmaphorum

OCTOBER 6, 2022

Disease modelling Gulf War Illness. In the mid-to-late 1990s, an unexplained illness began to emerge in army bases across the US. Symptoms and their severity ranged across individuals, and included fatigue, musculoskeletal pain, skin rashes, headaches, and gastrointestinal issues. Tinker, tailor, soldier, therapy.

In-Vivo 98

In-Vivo Research Genetics Drugs 98

pharmaphorum

SEPTEMBER 15, 2022

Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo engineering technology. Our ambition at Capstan is to invent new clinical paradigms through targeted in vivo reprogramming of cells.

In-Vivo 105

In-Vivo Engineer Scientist Life Science 105

The Pharma Data

JANUARY 12, 2021

13, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

pharmaphorum

APRIL 29, 2021

To achieve this, the agenda will allow delegates to: Explore the translation of BBB-penetrating antibodies to non-human primates , and new possibilities for in vivo brain imaging of antibody neuropharamacokinetics. A Meeting Point for the Field’s Experts. About Hanson Wade.

Drug Delivery 52

Drug Delivery Gene Therapy In-Vivo Antibody 52

The Pharma Data

MARCH 2, 2021

billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life. The companies share the goal of providing new obesity therapies with increased tolerability that support greater weight loss than current therapy options. population will have obesity. About Boehringer Ingelheim.

In-Vivo 52

In-Vivo Contract Manufacturing Bioinformatics Clinical Development 52

The Pharma Data

DECEMBER 9, 2020

The creation of Overland isn’t the only exciting thing happening for international life sciences companies and organizations. A solution could be at hand with Overland Pharmaceuticals. Overland aims to build a leading, fully integrated biopharma company by leveraging global networks and formative R&D partnerships.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

XTalks

DECEMBER 13, 2023

The recurrence of these events, or crises, can lead to life-threatening disabilities and/or early death. The landmark approvals were awarded to bluebird bio’s Lyfgenia (lovo-cel) and Vertex Pharmaceuticals and CRISPR Therapeutics’ jointly developed Casgevy (exa-cel). Casgevy is also the first ever CRISPR/Cas9-based therapy approved in the US.

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

The Pharma Data

JANUARY 12, 2021

Nielsen of Vivo Capital and Vanessa Malier of Kurma Partners will join IO Biotech’s board of directors as part of the closing of the financing. COPENHAGEN, Denmark , Jan. Additionally, Dr. Priyanka Belawat of HBM Partners, Jack B. ” “HBM is excited to be joining IO Biotech as a shareholder. .

In-Vivo 52

In-Vivo Antibody Vaccination Vaccine 52

Drug Discovery World

DECEMBER 13, 2023

This article is sponsored by Fortis Life Sciences. Fortis Life Sciences offers custom antibody discovery and manufacturing services for antibodies and single-domain antibodies, supporting the drug discovery market. Moreover, custom antibodies are a key reagent in companion diagnostics for these novel therapeutics.

Life Science 59

Life Science Antibody Manufacturing In-Vivo 59

Drug Discovery World

NOVEMBER 16, 2022

In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery process. . 2D vs 3D . 2D biology has been used by pharmaceutical researchers for decades.

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

XTalks

NOVEMBER 3, 2023

Related: Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug The advisors appeared convinced that exa-cel can offer significant benefits to people with sickle cell. Vertex and CRISPR Therapeutics are also seeking approval for exa-cel in beta thalassemia, the decision for which is set for March 30, 2024.

Gene Therapy 59

Gene Therapy Gene Gene Editing In-Vivo 59

XTalks

APRIL 24, 2023

Rare diseases can often be progressive, chronic and fatal. Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. Sadly, one-third of children with rare diseases die before their first birthday.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

Delveinsight

FEBRUARY 11, 2021

Verily, Google’s life-science-focused sibling company and Janssen will also seek to tap into the data generated by people during their everyday lives to seek for any previous health-related signals in the two years leading up to the point they consented to participate in the study as well as in the two years after.

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

XTalks

FEBRUARY 27, 2024

TIL vs CAR T-Cell Therapies While CAR T-cell therapies involve inserting a CAR engineered to target a specific cancer cell protein into a patient’s T cells, TIL-based T-cell therapies like Amtagvi involve separating TILs from a patient’s tumor (in autologous therapies) and expanding them ex vivo.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

Drug Discovery World

OCTOBER 13, 2022

The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK. Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery.

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

The Pharma Data

APRIL 22, 2023

“To our knowledge, this study is the first to show in vivo [in a living organism] protection against severe COVID-19 by an AI-designed T-cell vaccine,” said Girish Kirimanjeswara, associate professor of veterinary and biomedical sciences, Penn State. The results were published on April 11 in Frontiers in Immunology.

Vaccination 40

Vaccination Vaccine Protein Antibody 40

Pharma in Brief

JUNE 14, 2022

The Court dismissed allegations that the asserted patent claims were invalid for obviousness, lack of utility, overbreadth, and insufficiency of disclosure. Background. Janssen Inc. Janssen ) markets OPSUMIT® in Canada for the treatment of pulmonary arterial hypertension ( PAH ). OPSUMIT® is a tablet containing macitentan. Sandoz Canada Inc.

Containment 52

Containment In-Vivo Regulation Production 52

XTalks

AUGUST 17, 2020

This typically involves taking T cells from the body, engineering chimeric receptor antigens (CAR) and inserting them into the cells, expanding the cells ex vivo and injecting them back into the body. Cell-Based Immunotherapy vs. Immune Biologics. Immunotherapy involves leveraging components of the immune system (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Pharma in Brief

FEBRUARY 3, 2021

In one of its first patent decisions of 2021 , the Federal Court tackled arguments regarding the relevant date for insufficiency allegations and the level of disclosure required for demonstrated utility. The Court resolved these and other issues in the patentees’ favour, granting declarations of infringement against two proposed apixaban generics.

In-Vivo 52

In-Vivo Regulation Compliance Life Science 52

Drug Discovery World

APRIL 3, 2023

As life science operates globally, the vision for the business was always to bring aptamers as an antibody alternative to researchers worldwide. What advice would you offer to similar start-ups?    AT: Integral to Aptamer Group’s offering is an in-depth understanding of molecular science.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

APRIL 25, 2024

The market for cell line development is currently rising due to an increased focus by the life sciences sector on biopharmaceuticals and targeted therapies. For drug discovery and development, cell lines allow researchers to test the efficacy of therapeutics before moving into in vivo studies.

Development 59

Development Protein In-Vivo Life Science 59

XTalks

AUGUST 5, 2020

In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research. The Power of Single Cell Technology.

Gene Expression 112

Gene Expression Development RNA Drugs 112

XTalks

AUGUST 12, 2020

Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.

RNA 52

RNA Protein DNA In-Vivo 52

Drug Discovery World

NOVEMBER 23, 2023

Further publications are anticipated. The OBN Awards The OBN Awards, now in their 15 th year, are an awards programme for the life sciences industry, designed to celebrate innovation and outstanding achievement across all corners of the industry.

In-Vivo 59

In-Vivo Life Science Drugs Clinical Trials 59

Drug Discovery World

SEPTEMBER 6, 2022

This area of medicine, which turns our own bodies into agents of combat to fight disease, has quickly become one of the most promising fields in treating deadly diseases such as cancer, central nervous system disorders and even musculoskeletal conditions. . Last year saw the sector surge, with levels of investment hitting an all-time high at $22.7

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

APRIL 15, 2024

Reece Armstrong speaks to Sean McClain , Founder & CEO of Absci about the rise of generative AI in life sciences. The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications.

Antibody 59

Antibody Drugs In-Vivo Life Science 59

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Pharmaceutical Technology

MAY 24, 2023

Autologous therapies are characterized as a circular supply chain; the patient’s own sample starts the supply chain, and it is then subjected to ex-vivo modifications with the resulting therapy administered back to that same patient. What are the general differences in the supply chain of CGT vs. traditional clinical trials?

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246